A multifaceted 'omics' approach for addressing the challenge of antimicrobial resistance

Future Microbiology

Volumn 10, Issue 3, 2015, Pages 365-376

  Cohen, Asi ^a   Bont, Louis ^b   Engelhard, Dan ^c   Moore, Edward ^d   Fernández, David ^e   Kreisberg Greenblatt, Racheli ^f   Oved, Kfir ^a   Eden, Eran ^a   Hays, John P ^g  

^a MeMed Diagnostics   (Israel)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Noray Bioinformatics   (Spain)

^f Ibexperts Ltd   (Israel)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic resistance; Bioinformatics; Genomics; Mass spectrometry; Microbiota; Proteomics; Transcriptomics

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BIOMICS; CLINICAL RESEARCH; DECISION SUPPORT SYSTEM; DIAGNOSIS; GENOMICS; HOST; HUMAN; IMMUNE RESPONSE; INTERNET; MICROBIOME; MICROFLORA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; BACTERIAL INFECTIONS; BACTERIUM; BIOLOGY; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; DRUG UTILIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PERSONALIZED MEDICINE; PROCEDURES; VIRUS DISEASES;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMPUTATIONAL BIOLOGY; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; GENOMICS; HUMANS; MICROBIOTA; PRECISION MEDICINE; PROTEOMICS; VIRUS DISEASES;

EID: 84926146974     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/FMB.14.127     Document Type: Review

References (81)

1. CDC. Threat Report 2013. Antimicrobial Resistance. www.cdc.gov
2. CDC - About Antimicrobial Resistance. www.cdc.gov/drugresistance/about.html
3. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med. 346(5), 334-339 (2002).
4. Craig JC, Williams GJ, Jones M et al. The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15,781 febrile illnesses (2010). www.ncbi.nlm.nih.gov
5. Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch. Intern. Med. 161(17), 2099-2104 (2001).
6. Caterino JM, Hiestand BC, Martin DR. Quality of care in elder emergency department patients with pneumonia: a prospective cohort study. BMC Emerg. Med. 8, 6 (2008).
7. Houck PM. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 164(6), 637-644 (2004).
8. Zwart S, Sachs AP, Ruijs GJ, Gubbels JW, Hoes AW, de Melker RA. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. BMJ 320(7228), 150-154 (2000).
9. Little P. Delayed prescribing of antibiotics for upper respiratory tract infection. BMJ 331(7512), 301-302 (2005).
10. Spiro DM, Tay K-Y, Arnold DH, Dziura JD, Baker MD, Shapiro ED. Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial. J. Am. Med. Assoc. 296(10), 1235-1241 (2006).
11. Fauci AS, Marston HD. The perpetual challenge of antimicrobial resistance. JAMA 311(18), 1853-1854 (2014).
12. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. J. Am. Med. Assoc. 281(1), 61-66 (1999).
13. Hollis A, Ahmed Z. Preserving antibiotics, rationally. N. Engl. J. Med. 369(26), 2474-2476 (2013).
14. CDC. Get smart: fast facts about antibiotic resistance. www.cdc.gov
15. European Surveillance of Antimicrobial Consumption Network (ESAC-Net). www.ecdc.europa.eu
16. WHO Europe. Data and statistics. www.euro.who.int
17. WHO. Antimicrobial resistance. www.who.int
18. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N. Engl. J. Med. 360(5), 439-443 (2009).
19. Niemz A, Ferguson TM, Boyle DS. Point-of-care nucleic acid testing for infectious diseases. Trends Biotechnol. 29(5), 240-250 (2011).
20. Craw P, Balachandran W. Isothermal nucleic acid amplification technologies for point-of-care diagnostics: a critical review. Lab. Chip. 12(14), 2469-2486 (2012).
21. Kim KH, Shin JH, Kim SY. The clinical significance of nasopharyngeal carriages in immunocompromised children as assessed. Korean J. Hematol. 44(4), 220-226 (2009).
22. Shin JH, Han HY, Kim SY. Detection of nasopharyngeal carriages in children by multiplex reverse transcriptase-polymerase chain reaction. Korean J. Pediatr. 52(12), 1358 (2009).
23. Jung CL, Lee MA, Chung WS. Clinical evaluation of the multiplex PCR Assay for the detection of bacterial pathogens in respiratory specimens from patients with pneumonia. Korean J. Clin. Microbiol. 13(1), 1358-1363 (2010).
24. Rhedin S, Lindstrand A, Rotzén-Östlund M et al. Clinical utility of PCR for common viruses in acute respiratory illness. Pediatrics 133(3), e538-e545 (2014).
25. Bogaert D, De Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 4(3), 144-154 (2004).
26. Spuesens EBM, Fraaij PLA, Visser EG et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: An observational study. PLoS Med. 10(5), e1001444 (2013).
27. Laxminarayan R, Duse A, Wattal C et al. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 13(12), 1057-1098 (2013).
28. Aderem A, Adkins JN, Ansong C et al. A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm. mBio 2(1), e00325-e00310 (2011).
29. Cooper MA, Shlaes D. Fix the antibiotics pipeline. Nature 472(7341), 32 (2011).
30. Press Announcements - new FDA task force will support innovation in antibacterial drug development. www.fda.gov
31. Kirby T. Europe to boost development of new antimicrobial drugs. Lancet 379(9833), 2229-2230 (2012).
32. IMS Institute. Responsible Use of Medicines Report 2012. www.imshealth.com
33. Too Many Antibiotics! Patients and Prescribers Speak Up. www.medscape.com
34. Tailored-Treatment. www.tailored-treatment.eu
35. Tailored-Treatment. Goals and concept. www.tailored-treatment.eu/?page-id=7
36. Laing RE, Hess P, Shen Y, Wang J, Hu SX. The role and impact of SNPs in pharmacogenomics and personalized medicine. Curr. Drug Metab. 12(5), 460-486 (2011).
37. Hofker M, Fu J, Wijmenga C. The genome revolution and its role in understanding complex diseases. Biochim. Biophys. Acta. 1842(10), 1889-1895 (2014).
38. Chapman SJ, Hill AVS. Human genetic susceptibility to infectious disease. Nat. Rev. Genet. 13(3), 175-188 (2012).
39. Emonts M, Hazelzet JA, de Groot R, Hermans PWM. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 3(9), 565-577 (2003).
40. Brouwer MC, de Gans J, Heckenberg SGB, Zwinderman AH, van der Poll T, van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 9(1), 31-44 (2009).
41. Boyd JH, Russell JA, Fjell CD. The meta-genome of sepsis: host genetics, pathogens and the acute immune response. J. Innate Immun. 6(3), 272-283 (2014).
42. Ruimy R, Angebault C, Djossou F et al. Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans? J. Infect. Dis. 202(6), 924-934 (2010).
43. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
44. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology 138(4), 1338-1345, 1345.e1-7 (2010).
45. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
46. Ochi H, Maekawa T, Abe H et al. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations. J. Gen. Virol. 92(Pt 5), 1071-1081 (2011).
47. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002).
48. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B∗5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002).
49. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B∗5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004).
50. Colombo S, Rauch A, Rotger M et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 198(6), 864-867 (2008).
51. Young B, Squires K, Patel P et al. First large, multicenter, open-label study utilizing HLA-B∗5701 screening for abacavir hypersensitivity in North America. AIDS Lond. Engl. 22(13), 1673-1675 (2008).
52. Mejias A, Suarez NM, Ramilo O. Detecting specific infections in children through host responses: a paradigm shift. Curr. Opin. Infect. Dis. 27(3), 228-235 (2014).
53. Ramilo O, Mejías A. Shifting the paradigm: host gene signatures for diagnosis of infectious diseases. Cell Host Microbe 6(3), 199-200 (2009).
54. Huang Y, Zaas AK, Rao A et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet. 7(8), e1002234 (2011).
55. Woods CW, McClain MT, Chen M et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PloS ONE 8(1), e52198 (2013).
56. Zaas AK, Chen M, Varkey J et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6(3), 207-217 (2009).
57. Ramilo O, Allman W, Chung W et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109(5), 2066-2077 (2007).
58. Mahajan P, Ramilo O, Kuppermann N. The future possibilities of diagnostic testing for the evaluation of febrile infants. JAMA Pediatr. 167(10), 888-898 (2013).
59. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 9(6), 703-719 (2012).
60. Kato K. Impact of the next generation DNA sequencers. Int. J. Clin. Exp. Med. 2(2), 193-202 (2009).
61. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10(1), 57-63 (2009).
62. Peng X, Gralinski L, Armour CD et al. Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. mBio 1(5) e00206-10 (2010).
63. Gill SR, Pop M, Deboy RT et al. Metagenomic analysis of the human distal gut microbiome. Science 312(5778), 1355-1359 (2006).
64. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13(4), 260-270 (2012).
65. Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology 146(6), 1564-1572 (2014).
66. Pflughoeft KJ, Versalovic J. Human microbiome in health and disease. Annu. Rev. Pathol. 7, 99-122 (2012).
67. Madupu R, Szpakowski S, Nelson KE. Microbiome in human health and disease. Sci. Prog. 96(Pt 2), 153-170 (2013).
68. Human Microbiome Project DACC - home. www.hmpdacc.org/
69. Human Microbiome Project - home. http://commonfund.nih.gov/hmp/index
70. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 30(1), 759-795 (2012)
71. Pérez-Cobas AE, Gosalbes MJ, Friedrichs A et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 62(11), 1591-1601 (2012).
72. Lan Y, Kriete A, Rosen GL. Selecting age-related functional characteristics in the human gut microbiome. Microbiome 1(1), 2 (2013).
73. Karlsson R, Davidson M, Svensson-Stadler L et al. Strain-level typing and identification of bacteria using mass spectrometry-based proteomics. J. Proteome Res. 11(5), 2710-2720 (2012).
74. Chooneea D, Karlsson R, Encheva V, Arnold C, Appleton H, Shah H. Elucidation of the outer membrane proteome of Salmonella enterica serovar Typhimurium utilising a lipid-based protein immobilization technique. BMC Microbiol. 10, 44 (2010).
75. Lloyd S. Least squares quantization in PCM. IEEE Trans. Inf. Theory 28(2), 129-137 (1982).
76. Cai H, Ruan P, Ng M, Akutsu T. Feature weight estimation for gene selection: a local hyperlinear learning approach. BMC Bioinformatics 15(1), 70 (2014).
77. Srikant R, Agrawal R. Mining generalized association rules. Future Gener. Comput. Syst. 13(2-3), 161-180 (1997).
78. Salzberg SL. C4.5: Programs for Machine Learning by J. Ross Quinlan. Morgan Kaufmann Publishers, Inc., 1993. Mach. Learn. 16(3), 235-240 (1994).
79. Tenenbaum JB, de Silva V, Langford JC. A global geometric framework for nonlinear dimensionality reduction. Science 290(5500), 2319-2323 (2000).
80. Durmu Tekir SD, Ülgen KÖ. Systems biology of pathogen-host interaction: networks of protein-protein interaction within pathogens and pathogen-human interactions in the post-genomic era. Biotechnol. J. 8(1), 85-96 (2013).
81. InformationWeek. 10 wearable health tech devices to watch. www.informationweek.com